Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ashwagandha as Adjunctive Therapy in Schizophrenia
NCT07917637Completed
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Randomised, double-blind trial in schizophrenia comparing Ashwagandha Plus Risperidone with Placebo Plus Risperidone (2 arms). Primary endpoint: Serum Tumor Necrosis Factor-alpha Concentration at 8 weeks. Started Mar 2026; status: completed.
02
Drugs
withania somnifera
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07917637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917637.